symbol PRGO
会社名 Perrigo Company plc (PRGO ペリゴ)
業種 医薬品   医療関連(Health Care)
概要 事業概要 ぺリゴ(Perrigo Company PLC)(旧名: Perrigo Company Limited)は店頭(OTC)消費財および専門製薬会社である。同社は消費者ヘルスケア(CHC)事業、ブランド消費者医療(BCH)事業、処方薬(Rx)事業および専門科学事業を運営する。同社はOTCヘルスケア製品を製造し、店舗ブランド市場向けの乳児用調合乳を供給する。また、一般的な拡張局所処方製品を提供する。CHC事業は、OTC店舗ブランド製品の販売に従事する。BCH事業は、多数の欧州のOTCブランドを開発・製造・販売・流通する。専門科学事業は、多発性硬化症の治療に重点を置いた資産、特に医薬品Tysabriを含む。  ペリゴはアイルランドの大手製薬会社。咳や風邪、アレルギ―用などの市販薬、ジェネリック、処方箋薬を扱う。市場は米国、英国、メキシコイスラエル、オ―ストラリア、カナダ中国と南米。また、多発性硬化症の治療に焦点を当てた薬を開発、製造する。その他に、乳幼児向け飲料や離乳食、栄養サプリメントも扱う。本社はダブリン。  
本社所在地 The Sharp Building Hogan Place Dublin 2 IRL
代表者氏名 Marry Laurie Brlas
代表者役職名 Independent Chairman of the Board
電話番号 +353 1-709-4000
設立年月日 41426
市場名 NYSE(ニューヨーク証券取引所)
従業員数 10600人
EBITDA EBITDA(百万ドル) 905.50000
時価総額 時価総額(百万ドル) 6543.64700
売上高 売上高(百万ドル) 4731.70000
企業価値(EV) 企業価値(EV)(百万ドル) 9232.94700
当期純利益 当期純利益(百万ドル) 130.90000
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Perrigo Company PLC revenues decreased 4% to $4.73B. Net income before extraordinary items decreased 3% to $131M. Revenues reflect RX Pharmaceuticals segment decrease of 15% to $824.2M Other segment decrease from $55.6M to $0K CHCA segment decrease of 1% to $2.41B. Net income also reflects CHCA segment income decrease of 67% to $147.6M RX Pharmaceuticals segment income decrease of 28% to $222.6M.



   Earnings : What to expect NYSE:PRGO NYSE:APTS NASDAQ:STRL NYSE:GMRE and #Covid-19 (#Coronavirus) impact  2021/03/05 18:28:00 Stock Market Daily
Earnings, Analyst opinion and estimate and latest Covid-19 (Coronavirus) impact on these hot stocks to invest
   Clarityne Market 2021 Business Development, Size, Share, Analysis And Opportunities To 2028 | Bayer AG, Perrigo company plc., Sun Pharmaceutical Industries Ltd., Apotex Inc, Pfizer Inc., Sandoz International  2021/03/03 13:31:19 OpenPR
Allied Market Research (USA, Oregon, Portland) Published Latest Report titled, ‘Clarityne Market: Global Opportunity Analysis and Industry Forecast 2021-2028’. The Clarityne Market is expected to witness growth in upcoming years due to factors such as increase in target patient population, which
   Perrigo Company PLC (PRGO) Q4 2020 Earnings Call  2021/03/02 19:14:23 AlphaStreet
Perrigo Company PLC (NYSE: PRGO) Q4 2020 earnings call dated Mar. 01, 2021 Corporate Participants: Bradley Joseph — Vice President, Global Investor Relations & Corporate Communications Murray S. Kessler — President & Chief Executive Officer […] The post Perrigo Company PLC (PRGO) Q4 2020 Earnings Call first appeared on AlphaStreet .
   Perrigo (NYSE:PRGO) Issues Quarterly Earnings Results, Misses Expectations By $0.07 EPS  2021/03/02 13:50:42 Transcript Daily
Perrigo (NYSE:PRGO) released its quarterly earnings results on Sunday. The company reported $0.93 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.00 by ($0.07), MarketWatch Earnings reports. The firm had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.33 billion. Perrigo had a positive return on […]
   NRG Energy, Perrigo rise; Athenex, Ontrak fall  2021/03/01 21:10:49 ABC News
Stocks that traded heavily or had substantial price changes Monday: NRG Energy, Perrigo rise; Athenex, Ontrak fall
   Perrigo to Present Virtually at Upcoming Investor Conferences  2020/12/17 13:03:00 PR Newswire
DUBLIN, Dec. 17, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that EVP and President of Consumer Self-Care Americas, Rich Sorota will present at the ICR Conference at 11:30 AM EST on Monday, January 11, 2021. Perrigo President & CEO Murray S. Kessler and…
   Should Value Investors Consider Perrigo (PRGO) Stock Now?  2020/12/10 14:40:02 Yahoo Finance
Let's see if Perrigo Company plc (PRGO) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
   Clinical Nutrition Market to Show Vigorous Growth With Industry’s Leading Players like B. Braun Melsungen AG, Abbott Laboratories, Perrigo Company Plc, GroupeDanone, Hospira, Inc, Fresenius Kabi AG and others through 2027  2020/12/09 14:40:33 OpenPR
Clinical Nutrition Market Overview: The global clinical nutrition market report discusses possibilities for the market attaining an impressive CAGR during the forecast period of 2019-2027. Market Research Future (MRFR) predicts the possibility of clinical nutrition market size transcending the expected
   Global Nicotine Gum Market Trajectory & Analytics Report 2020-2027 Featuring Cambrex, Fertin Pharma, GlaxoSmithKline, Johnson & Johnson, Perrigo, Pfizer, Reynolds American -  2020/12/09 09:59:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Nicotine Gum - Global Market Trajectory & Analytics" report has been added to's offering. Global Nicotine Gum Market to Reach US$6.5 Billion by the Year 2027 Amid the COVID-19 crisis, the global market for Nicotine Gum estimated at US$5.2 Billion in the year 2020, is projected to reach a revised size of US$6.5 Billion by 2027, growing at a CAGR of 3% over the analysis period 2020-2027. 2 mg, one of the segments analyzed in the report, is
   Pediatric Healthcare Market to Witness Huge Growth by 2026 | Perrigo, Nestlé, Danone, AstraZeneca  2020/12/02 19:28:31 OpenPR
Global Pediatric Healthcare Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread) is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and

 関連キーワード  (医薬品 米国株 PRGO ペリゴ PRGO )

 twitter  (公式ツイッターやCEOツイッターなど)